Tag: loncastuximab tesirine

EHA 2025 & ICML: LOTIS-7 Study Loncastuximab Tesirine + Glofitamab Demonstrates Early Efficacy in R/R DLBCL

wo clinical trials testing the antibody loncastuximab tesirine (Zynlonta® ADC Therapeutics) showed encouraging results in the treatment of patients diagnosed with high-risk forms of two blood cancers – follicular lymphoma (FL) and marginal zone lymphoma (MZL).

ongoing LOTIS-7 Phase 1b open-label clinical trial (NCT04970901) evaluating the safety and efficacy of loncastuximab tesirine (Zynlonta®; ADC Therapeutics; See: Drugmap) in combination with the bispecific antibody glofitamab (Columvi™; Genentech/Roche)

Swedish Orphan Biovitrum (Sobi®) has signed an exclusive license agreement with ADC Therapeutics to develop and commercialize loncastuximab tesirine (Zynlonta®) for use in hematologic...

ADC Therapeutics and Mitsubishi Tanabe Pharma Corporation have signed an exclusive license agreement for the development and commercialization of loncastuximab tesirine (ADCT-402; Zynlonta®; ADC...

The European Commission has granted Orphan Drug Designation to loncastuximab tesirine (Zynlonta®; ADC Therapeutics); previously known as ADCT-402, a CD19-targeted ADC, for the treatment...

The United States Food and Drug Administration’s (FDA) program to accelerate approval of some promising therapeutic agents has recently come under fire due to...

Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has announced the acquisition of ADC Biotechnology, a UK-based bioconjugation development services business specializing...

Diffuse large B-cell lymphoma (DLBCL), a form of non-Hodgkin lymphoma, is the most common form of blood cancer. Lymphomas occur when cells of the...

The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for loncastuximab tesirine, previously known as ADCT-402. The investigational agent is...